Evidence map›Paper›PMID 32654370›Full record

ArticleFEBS open bio2020

Serum long non-coding RNA LINC00887 as a potential biomarker for diagnosis of renal cell carcinoma.

Junjie Xie, Yu Zhong, Rong Chen, Gang Li, Yongwen Luo, Jintao Yang, Zhongwei Sun, Yanzhong Liu, Peipei Liu, Na Wang and 3 more

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Epigenetic Biomarkers of Renal Cell Carcinoma for Liquid Biopsy Tests.International journal of molecular sciences · 2021
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Junjie XieDepartment of Urology, Eighth Medical Center, Chinese PLA General Hospital, Beijing, China.
Yu ZhongDepartment of Urology, 958th Hospital of PLA, Southwest Hospital, Army Medical University, Chongqing, China.
Rong ChenCenter of Clinical Laboratory, First Medical Center, Chinese PLA General Hospital, Beijing, China.
Gang LiDepartment of Urology, Eighth Medical Center, Chinese PLA General Hospital, Beijing, China.
Yongwen LuoDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Jintao YangDepartment of Urology, Eighth Medical Center, Chinese PLA General Hospital, Beijing, China.
Zhongwei SunDepartment of Urology, 967th Hospital of PLA, Dalian, China.
Yanzhong LiuDepartment of Urology, Eighth Medical Center, Chinese PLA General Hospital, Beijing, China.
Peipei LiuCenter of Clinical Laboratory, First Medical Center, Chinese PLA General Hospital, Beijing, China.
Na WangOutpatient Comprehensive Treatment Area, First Medical Center, Chinese PLA General Hospital, Beijing, China.
Jiaqi AnShandong First Medical University, Shandong, China.
Chao LiDepartment of Urology, Eighth Medical Center, Chinese PLA General Hospital, Beijing, China.
Yang SongCenter of Clinical Laboratory, First Medical Center, Chinese PLA General Hospital, Beijing, China.ORCID 0000-0003-4301-961X
Chinese PLA General Hospital · CNArmy Medical University · CNSeventh People's Hospital of Dalian · CNShandong First Medical University · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of non-invasive biomarkers for the detection of renal cell carcinoma (RCC) in early-stage patients may help improve disease outcome. Certain long non-coding RNAs (lncRNAs) have been reported to be possible biomarkers for the diagnosis and prognosis of cancer. Here, we examined the suitability of the lncRNA LINC00887 as a potential biomarker for RCC because its expression has been shown to be elevated in RCC tissue versus normal tissue in the Gene Expression Profiling Interactive Analysis (GEPIA) database. We found that LINC00887 expression is significantly increased in early-stage RCC tissues and the serum of early-stage RCC patients compared to matched normal tissues and the serum of healthy subjects, respectively. We also demonstrated that elevated serum LINC00887 is generated from the tumor tissues of RCC patients. Moreover, a receiver operating characteristic (ROC) curve was generated to analyze the diagnostic value of serum LINC00887. The area under the ROC cure differentiating early-stage RCC patients from healthy subjects was 0.8001, with a sensitivity of 71.05% and a specificity of 89.87%. Furthermore, we found that LINC00887 promotes RCC cell proliferation in vitro. Taken together, our findings suggest that a serum LINC00887 signature is associated with RCC cell proliferation and may be a potential biomarker for the detection of early-stage RCC.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleMiddle AgedRNA, Long NoncodingBiomarkers, TumorRNA, Long Noncodingbiomarkercell proliferationLINC00887renal cell carcinoma

Identifiers

PMID32654370
PMCPMC7459398
OpenAlexW3041889378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.